Table 3.

Anti-Hyperglycemic Activity of the Repeated Doses of Solvent Fraction in STZ-Induced Diabetic Mice

Fasting Blood Glucose Level (mg/dl)				% Reduction
Group	Baseline	7th day	14th day	7th day	14th day
DC	342.83±7.23nC	345.33±7.21nC	351.33±9.82nC	−0.729	−2.48
GLC5 mg/kg	338.33±12.06nC	147.83±9.56aC, βC, nC	136.50±5.81aC, βC, nC	56.31	59.66
AQF100 mg/kg	347.50±9.02 nC	243.83±7.77aC, βC, nC	231.83±10.29aC, βC, nC	29.83	33.29
AQF200 mg/kg	339.50±16.54nC	220.17±8.78aC, βC, nC	208.50±13.85aC, βC, nC	35.15	38.59
AQF400 mg/kg	362.33±13.64nC	195.00±5.85aC, βC, nC	171.33±7.83aC, βC, nC	46.18	52.71
NC	85.83±14.85aC	87.67±2.69aC	84.50±2.96 aC	−2.14	1.55

Notes: Each value represents mean ± SEM; n=6 for each group. ^aCompared to the diabetic control, ⁿcompared to the normal control, and ^βcompared to baseline blood glucose level. ^Cp < 0.001.

Abbreviations: DC, Diabetic control; NC, Normal control; GLC, glibenclamide; AQF, aqueous fraction.